FII Holdings

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC
BSE5495.15195.15 (+3.68 %)
PREV CLOSE ( ) 5300.00
OPEN PRICE ( ) 5381.00
BID PRICE (QTY) 5495.10 (6)
OFFER PRICE (QTY) 5512.50 (2)
VOLUME 739
TODAY'S LOW / HIGH ( )5349.25 5514.70
52 WK LOW / HIGH ( )3119.9 7208
NSE5492.80160.55 (+3.01 %)
PREV CLOSE( ) 5332.25
OPEN PRICE ( ) 5377.00
BID PRICE (QTY) 5493.00 (1)
OFFER PRICE (QTY) 5498.95 (2)
VOLUME 4578
TODAY'S LOW / HIGH( ) 5335.35 5510.00
52 WK LOW / HIGH ( )3115.05 7220.95
upfii downfii 
Current Quarter
Prev Quarter
Company Quarter Ended 202403 % of Share Quarter Ended 202312 % of Share Changeupfii

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.